These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
124 related articles for article (PubMed ID: 11052627)
1. Expression of pRB, cyclin/cyclin-dependent kinases and E2F1/DP-1 in human tumor lines in cell culture and in xenograft tissues and response to cell cycle agents. Lu K; Shih C; Teicher BA Cancer Chemother Pharmacol; 2000; 46(4):293-304. PubMed ID: 11052627 [TBL] [Abstract][Full Text] [Related]
2. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031 [TBL] [Abstract][Full Text] [Related]
3. Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells. Zhu WY; Jones CS; Kiss A; Matsukuma K; Amin S; De Luca LM Exp Cell Res; 1997 Aug; 234(2):293-9. PubMed ID: 9260897 [TBL] [Abstract][Full Text] [Related]
4. Flavopiridol, a cyclin-dependent kinase inhibitor, prevents spindle inhibitor-induced endoreduplication in human cancer cells. Motwani M; Li X; Schwartz GK Clin Cancer Res; 2000 Mar; 6(3):924-32. PubMed ID: 10741717 [TBL] [Abstract][Full Text] [Related]
5. Flavopiridol, a novel cyclin-dependent kinase inhibitor, suppresses the growth of head and neck squamous cell carcinomas by inducing apoptosis. Patel V; Senderowicz AM; Pinto D; Igishi T; Raffeld M; Quintanilla-Martinez L; Ensley JF; Sausville EA; Gutkind JS J Clin Invest; 1998 Nov; 102(9):1674-81. PubMed ID: 9802881 [TBL] [Abstract][Full Text] [Related]
6. Flavopiridol-induced apoptosis during S phase requires E2F-1 and inhibition of cyclin A-dependent kinase activity. Jiang J; Matranga CB; Cai D; Latham VM; Zhang X; Lowell AM; Martelli F; Shapiro GI Cancer Res; 2003 Nov; 63(21):7410-22. PubMed ID: 14612540 [TBL] [Abstract][Full Text] [Related]
7. Cyclin E-cdk2 activation is associated with cell cycle arrest and inhibition of DNA replication induced by the thymidylate synthase inhibitor Tomudex. Yin MB; Guo B; Panadero A; Frank C; Wrzosek C; Slocum HK; Rustum YM Exp Cell Res; 1999 Feb; 247(1):189-99. PubMed ID: 10047461 [TBL] [Abstract][Full Text] [Related]
8. Induction of differentiation accompanies inhibition of Cdk2 in a non-small cell lung cancer cell line. Lee HR; Chang TH; Tebalt MJ; Senderowicz AM; Szabo E Int J Oncol; 1999 Jul; 15(1):161-6. PubMed ID: 10375610 [TBL] [Abstract][Full Text] [Related]
9. 20-Cyclopropyl-cholecalciferol vitamin D3 analogs: a unique class of potent inhibitors of proliferation of human prostate, breast and myeloid leukemia cell lines. Koike M; Koshizuka K; Kawabata H; Yang R; Taub HE; Said J; Uskokovic M; Tsuruoka N; Koeffler HP Anticancer Res; 1999; 19(3A):1689-97. PubMed ID: 10470102 [TBL] [Abstract][Full Text] [Related]
10. The cyclin-dependent kinase inhibitor (CDKI) flavopiridol disrupts phorbol 12-myristate 13-acetate-induced differentiation and CDKI expression while enhancing apoptosis in human myeloid leukemia cells. Cartee L; Wang Z; Decker RH; Chellappan SP; Fusaro G; Hirsch KG; Sankala HM; Dent P; Grant S Cancer Res; 2001 Mar; 61(6):2583-91. PubMed ID: 11289135 [TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo pharmacokinetic-pharmacodynamic relationships for the trisubstituted aminopurine cyclin-dependent kinase inhibitors olomoucine, bohemine and CYC202. Raynaud FI; Whittaker SR; Fischer PM; McClue S; Walton MI; Barrie SE; Garrett MD; Rogers P; Clarke SJ; Kelland LR; Valenti M; Brunton L; Eccles S; Lane DP; Workman P Clin Cancer Res; 2005 Jul; 11(13):4875-87. PubMed ID: 16000586 [TBL] [Abstract][Full Text] [Related]
12. Apigenin inhibits growth and induces G2/M arrest by modulating cyclin-CDK regulators and ERK MAP kinase activation in breast carcinoma cells. Yin F; Giuliano AE; Law RE; Van Herle AJ Anticancer Res; 2001; 21(1A):413-20. PubMed ID: 11299771 [TBL] [Abstract][Full Text] [Related]
13. Antiproliferative effect of 1alpha,25-dihydroxyvitamin D3 in human prostate cancer cell line LNCaP involves reduction of cyclin-dependent kinase 2 activity and persistent G1 accumulation. Zhuang SH; Burnstein KL Endocrinology; 1998 Mar; 139(3):1197-207. PubMed ID: 9492054 [TBL] [Abstract][Full Text] [Related]
14. Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells. Sweeney KJ; Swarbrick A; Sutherland RL; Musgrove EA Oncogene; 1998 Jun; 16(22):2865-78. PubMed ID: 9671407 [TBL] [Abstract][Full Text] [Related]
15. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Hiyama H; Iavarone A; LaBaer J; Reeves SA Oncogene; 1997 May; 14(21):2533-42. PubMed ID: 9191053 [TBL] [Abstract][Full Text] [Related]
16. Regulation of expression and activity of distinct pRB, E2F, D-type cyclin, and CKI family members during terminal differentiation of P19 cells. Gill RM; Slack R; Kiess M; Hamel PA Exp Cell Res; 1998 Oct; 244(1):157-70. PubMed ID: 9770359 [TBL] [Abstract][Full Text] [Related]
17. Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. Carlson B; Lahusen T; Singh S; Loaiza-Perez A; Worland PJ; Pestell R; Albanese C; Sausville EA; Senderowicz AM Cancer Res; 1999 Sep; 59(18):4634-41. PubMed ID: 10493518 [TBL] [Abstract][Full Text] [Related]
18. Interaction of retinoblastoma protein and D cyclins during cell-growth inhibition by hexamethylenebisacetamide in TM2H mouse epithelial cells. Said TK; Medina D Mol Carcinog; 1998 Jun; 22(2):128-43. PubMed ID: 9655257 [TBL] [Abstract][Full Text] [Related]
19. Selective sensitization of retinoblastoma protein-deficient sarcoma cells to doxorubicin by flavopiridol-mediated inhibition of cyclin-dependent kinase 2 kinase activity. Li W; Fan J; Bertino JR Cancer Res; 2001 Mar; 61(6):2579-82. PubMed ID: 11289134 [TBL] [Abstract][Full Text] [Related]
20. Cell cycle basis for the onset and progression of c-Myc-induced, TGFalpha-enhanced mouse mammary gland carcinogenesis. Liao DJ; Natarajan G; Deming SL; Jamerson MH; Johnson M; Chepko G; Dickson RB Oncogene; 2000 Mar; 19(10):1307-17. PubMed ID: 10713672 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]